NESACAINE- chloroprocaine hydrochloride injection, solution

Valsts: Amerikas Savienotās Valstis

Valoda: angļu

Klimata pārmaiņas: NLM (National Library of Medicine)

Aktīvā sastāvdaļa:

Chloroprocaine Hydrochloride (UNII: LT7Z1YW11H) (Chloroprocaine - UNII:5YVB0POT2H)

Pieejams no:

General Injectables & Vaccines, Inc

SNN (starptautisko nepatentēto nosaukumu):

Chloroprocaine Hydrochloride

Kompozīcija:

Chloroprocaine Hydrochloride 10 mg in 1 mL

Ievadīšanas:

INFILTRATION

Receptes veids:

PRESCRIPTION DRUG

Ārstēšanas norādes:

Nesacaine 1% and 2% Injections, in multidose vials with methylparaben as preservative, are indicated for the production of local anesthesia by infiltration and peripheral nerve block. They are not to be used for lumbar or caudal epidural anesthesia. Nesacaine-MPF 2% and 3% Injections, in single dose vials without preservative and without EDTA, are indicated for the production of local anesthesia by infiltration, peripheral and central nerve block, including lumbar and caudal epidural blocks. Nesacaine and Nesacaine-MPF Injections are not to be used for subarachnoid administration. Nesacaine and Nesacaine-MPF Injections are contraindicated in patients hypersensitive (allergic) to drugs of the PABA ester group. Lumbar and caudal epidural anesthesia should be used with extreme caution in persons with the following conditions: existing neurological disease, spinal deformities, septicemia, and severe hypertension.

Produktu pārskats:

NESACAINE® (chloroprocaine HCL Injection, USP) with preservatives is supplied as follows: NESACAINE®-MPF (chloroprocaine HCL Injection, USP) without preservatives and without EDTA is supplied as follows: For single-dose vials: Discard unused portion. Keep from freezing. Protect from light. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. All trademarks are the property of Fresenius Kabi USA, LLC.

Autorizācija statuss:

New Drug Application

Produkta apraksts

NESACAINE- CHLOROPROCAINE HYDROCHLORIDE INJECTION, SOLUTION
GENERAL INJECTABLES & VACCINES, INC
----------
NESACAINE 1% 10MG/ML 30ML MULTIPLE DOSE VIAL
DESCRIPTION
Nesacaine and Nesacaine-MPF Injections are sterile non-pyrogenic local
anesthetics. The
active ingredient in Nesacaine and Nesacaine-MPF Injections is
chloroprocaine HCl
(benzoic acid, 4-amino-2-chloro-2-(diethylamino) ethyl ester,
monohydrochloride), which
is represented by the following structural formula:
The solutions are adjusted to pH 2.7 to 4.0 by means of sodium
hydroxide and/or
hydrochloric acid. Filled under nitrogen.
Nesacaine and Nesacaine-MPF Injections should not be resterilized by
autoclaving.
CLINICAL PHARMACOLOGY
Chloroprocaine, like other local anesthetics, blocks the generation
and the conduction of
nerve impulses, presumably by increasing the threshold for electrical
excitation in the
nerve, by slowing the propagation of the nerve impulse and by reducing
the rate of rise
of the action potential. In general, the progression of anesthesia is
related to the
diameter, myelination and conduction velocity of affected nerve
fibers. Clinically, the
order of loss of nerve function is as follows: (1) pain, (2)
temperature, (3) touch, (4)
proprioception, and (5) skeletal muscle tone.
Systemic absorption of local anesthetics produces effects on the
cardiovascular and
central nervous systems. At blood concentrations achieved with normal
therapeutic
doses, changes in cardiac conduction, excitability, refractoriness,
contractility, and
peripheral vascular resistance are minimal. However, toxic blood
concentrations depress
cardiac conduction and excitability, which may lead to
atrioventricular block and
ultimately to cardiac arrest. In addition, with toxic blood
concentrations myocardial
contractility may be depressed and peripheral vasodilation may occur,
leading to
decreased cardiac output and arterial blood pressure.
Following systemic absorption, toxic blood concentrations of local
anesthetics can
produce central nervous system stimulation, dep